Skip to main content
. 2021 Sep 8;70(12):2860–2870. doi: 10.2337/db21-0513

Figure 4.

Figure 4

Anti–TGF-β and anti–PD-1 dual antibody (ab) treatment render NOD.ChgA−/− mice susceptible to autoimmune diabetes. A: Representative FACS plots showing the percentage of indicated immune cell populations in the islets of NOD.ChgA−/− mice either treated with four injections of anti–TGF-β ab every 3 days or left untreated (control). Infiltration of leukocytes was analyzed 15 days postinitiation of treatment. B: Quantification of the percentage of indicated cell populations among total islet cells as described in panel A. Data (mean ± SEM) are pooled from three independent experiments. Each dot represents individual mouse. C: Experimental design of the anti–TGF-β and anti–PD-1 ab treatment. D: Incidence of diabetes in 8–10 week old NOD or NOD.ChgA−/− mice treated with anti–TGF-β either alone or in combination with anti–PD-1. Data are pooled from three independent experiments. P values were calculated by unpaired two-tailed Student t test. *P < 0.05. DC, dendritic cell; ns, not significant.